For decades, the bodybuilding world has treated myostatin like the Loch Ness Monster with a lab coat.
Everybody has heard of it. Everybody knows somebody who supposedly knows somebody who inhibited it. And every few years anothering like a Belgian Blue bull provided you’re willing to inject something manufactured behind a back-alley noodle shop
Well, something rather important just happened.
On Sept. 11, the FDA approved Scholar Rock’s Isembyld—apitegromab-mstn—for adults and children age 2 and older with spinal muscular atrophy (SMA) who are already receiving an SMN2-targeted therapy. More importantly for our little corner of the universe, it’s the first approved SMA treatment designed specifically to target the muscle itself.
And the target is myostatin.
What Is Isembyld (Apitegromab) & How Does It Target Myostatin?
Before somebody starts Googling “Isembyld bodybuilding cycle,” STOP!
SMA is a devastating genetic neuromuscular disease. This is a prescription medicine developed for with that condition, not a new contest-prep drug. Apitegromab is a monoclonal antibody administered by infusion, and its FDA indication has precisely nothing to do with making your arms bigger.
But the science is fascinating because the basic concept bodybuilders have obsessed over for years is real.
Myostatin is part of the body’s regulatory machinery limiting skeletal-muscle growth. Apitegromab binds precursor forms of myostatin—promyostatin and latent myostatin—and inhibits their activation. Rather than fixing the genetic cause of SMA, it’s intended to improve what happens downstream at the muscle.
That’s a significant distinction.
How Apitegromab Targets Myostatin
Modern SMA drugs have transformed treatment by addressing survival motor neuron biology. Yet even when you improve what’s happening upstream, damaged or underdeveloped muscle remains a problem. Scholar Rock’s idea was essentially: treat the neurological disease, and attack the muscle weakness from the other direction.
In the Phase 3 SAPPHIRE trial, patients were already receiving SMN2-targeted treatment. Adding apitegromab produced a 2.2-point advantage over placebo after a year on the Hammersmith Functional Motor Scale-Expanded. About 34% of patients receiving the drug improved by at least three points compared with 13.5% receiving placebo.
Those numbers are clinically meaningful improvements in motor function among people dealing with a serious disease.
And that’s exactly why the bodybuilding community shouldn’t degrade this story. But, eventually they will, they always do. The interesting implication isn’t that we’ve discovered pharmaceutical hypertrophy. It’s that manipulating muscle-growth regulation has crossed an important line from experimental biology into an FDA-approved medicine.
Could Myostatin Inhibitors Prevent Muscle Loss During Weight Loss?
Scholar Rock is already studying the broader implications. Reuters reports that the company is investigating its approach for preserving muscle during obesity-related weight loss—a potentially enormous market now that GLP-1 drugs are causing people to shed body weight by the truckload.
Now that should make anyone interested in physique development sit up.
Imagine obesity medicine evolving from merely lose weight toward lose fat while pharmacologically defending muscle.
But let’s not outrun the evidence. One approved drug for one neuromuscular disease doesn’t prove myostatin inhibition will safely build enormous amounts of useful muscle in healthy athletes. Muscle size, muscle quality, tendon adaptation, cardiovascular demands and actual athletic performance are not interchangeable concepts. Biology has an annoying habit of being more complicated than supplement advertising.
Still, Sept. 11, 2026, deserves a little asterisk in muscle building history, because after decades of speculation, failed candidates, Internet peptides and myostatin mythology, a therapy directly manipulating this pathway finally made it through the front door of American medicine.
And whenever medicine learns how to control skeletal muscle better, you can be damn certain bodybuilding will be watching through the window.
